Cardiorenal relationships and a role of vitamin D in patients with chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2018-28-5-613-621
Abstract
Cardiorenal relationships in patients with chronic obstructive pulmonary disease (COPD) are discussed in this review. Pathophysiology of cardiorenal syndrome is not fully understood, but supposed to be a complex condition resulted from neurohumoral activation, endothelial dysfunction, proteinuria, oxidative stress, uremia, and other factors. The airflow limitation in COPD could enhance those mechanisms. Recent studies discussed such therapeutic strategies as therapy of haemodymanic or neurohumoral abnormalities, but therapeutic approaches in this disease need further investigations. The lungs could play a role as a part of the cardiorenopulmonary syndrome. Effects of vitamin D on the main parameters of the cardiorenal syndrome and on COPD course have been published. Recent clinical and experimental findings consider vitamin D not only as a marker of the cardiorenal syndrome, but also as a therapeutic target in COPD.
About the Authors
E. V. Bolotova
Kuban State Medical University, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Elena V. Bolotova, Doctor of Medicine, Professor, Department of Therapy No.1, Faculty of Postgraduate Physician Training
ul. Sedina 4, Krasnodar, 350063
V. V. Yavlyanskaya
Kuban State Medical University, Healthcare Ministry of Russia;
Krasnodar Territorial Teaching Hospital No.2, Healthcare Ministry of Krasnodar krai
Russian Federation
Russian Federation
Valeriya V. Yavlyanskaya, Postgraduate Student, Department of Therapy No.1, Faculty of Postgraduate Physician Training, Kuban State Medical University, Healthcare Ministry of Russia; an endocrinologist and a therapeutist at Krasnodar Territorial Teaching Hospital No.2, Healthcare Ministry of Krasnodar krai
ul. Sedina 4, Krasnodar, 350063,
ul. Krasnykh partisan 6/2, Krasnodar, 350012
A. V. Dudnikova
Kuban State Medical University, Healthcare Ministry of Russia;
Krasnodar Territorial Teaching Hospital No.2, Healthcare Ministry of Krasnodar krai
Russian Federation
Russian Federation
Anna V. Dudnikova, Postgraduate Student, Department of Therapy No.1, Faculty of Postgraduate Physician Training, Kuban State Medical University, Healthcare Ministry of Russia; a therapeutist at Krasnodar Territorial Teaching Hospital No.2, Healthcare Ministry of Krasnodar krai
ul. Sedina 4, Krasnodar, 350063,
ul. Krasnykh partisan 6/2, Krasnodar, 350012
References
1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
2. Aisanov Z.R., Avdeev S.N., Arkhipov V.V. et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Pul’monologiya. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20 (in Russian).
3. Fedeli U., DeGiorgi A., Gennaro N. et al. Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 443–450. DOI: 10.2147/COPD.S119390.
4. Bolotova E.V., Dudnikova A.V. Chronic kidney disease in patients with chronic obstructive pulmonary disease: a role of exacerbations. Pul’monologiya. 2016; 26 (5): 578–583. DOI: 10.18093/0869-0189-2016-26-5-578-583 (in Russian).
5. Guazzi M., Gatto P., Giusti G. et al. Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung-right heart-kidney interaction. Int. J. Cardiol. 2013; 169 (6): 379–384. DOI: 10.1016/j.ijcard.2013.09.014.
6. Bolotova E.V., Dudnikova A.V. Particular risk factors for chronic kidney disease in patients with chronic obstructive pulmonary disease. Nefrologiya. 2015; 19 (5): 28–33 (in Russian).
7. van Gestel Y.R., Chonchol M., Hoeks S.E. et al. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. Nephrol. Dial. Transplant. 2009; 24 (9): 2763–2767. DOI: 10.1093/ndt/gfp171.
8. Chen C.Y., Liao K.M. Chronic obstructive pulmonary disease is associated with risk of chronic kidney disease: a nationwide case-cohort study. Sci. Rep. 2016; 6: 25855. DOI: 10.1038/srep25855.
9. Elmahallawy I.А., Qora A.M. Prevalence of chronic renal failure in COPD patients. Egypt. J. Chest Dis. Tuberc. 2013; 62 (2): 221–227. DOI: 10.1016/j.ejcdt.2013.02.005.
10. Gaddam S., Gunukula S.K., Lohr J.W., Arora P. Prevalence of chronic kidney disease in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC. Pulm. Med. 2016; 16 (1): 158. DOI: 10.1186/s12890-016-0315-0.
11. Xia J., Wang L., Ma Z. et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol. Dial. Transplant. 2017; 32 (3): 475–487. DOI: 10.1093/ndt/gfw452.
12. Miller J., Edwards L.D., Agustí A. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013; 107 (9): 1376–1384. DOI: 10.1016/j.rmed.2013.05.001.
13. Navaneethan S.D., Schold J.D., Huang H. et al. Mortality outcomes of patients with chronic kidney disease and chronic obstructive pulmonary disease. Am. J. Nephrol. 2016; 43 (1): 39–46. DOI: 10.1159/000444422.
14. Barakat M., McDonald H., Collier T. et al. Acute kidney injury in stable COPD and at exacerbation. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 2067–2077. DOI: 10.2147/COPD.S88759.
15. Schrier R.W. Role of diminished renal function in cardiovascular mortality: marker or pathogenic factor? J. Am. Coll. Cardiol. 2006; 47 (1): 1–8. DOI: 10.1016/j.jacc.2005.07.067.
16. Schrier R.W. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann. Intern. Med. 1990; 113 (2): 155–159. DOI: 10.7326/0003-4819-113-2-155.
17. Bolotova E.V., Dudnikova A.V., Eremeeva L.F., Kartavenkov S.A. Features of intrarenal blood flow in patients with chronic obstructive pulmonary disease. Klinicheskaya nefrologiya. 2016; (3-4): 22–26 (in Russian).
18. Padyganova A.V., Chicherina E.N. The role of concomitant course of chronic bronchial disease and arterial hypertension in development of functional kidney disorders. Arkhiv vnutrenney meditsiny. 2014; 4 (18): 47–51. Available at: https://www.medarhive.ru/jour/article/viewFile/320/321 (in Russian).
19. Barsukov A.V., Talantseva M.S., Korovin A.E., Kazantsev V.A. The problem of concomitant course of essential hypertension and chronic obstructive pulmonary disease. Cardiosomatica. 2012; (4): 12–17 (in Russian).
20. Domenech P., Perez T., Saldarini A. et al. Kidney-lung pathophysiological crosstalk: its characteristics and importance. Int. Urol. Nephrol. 2017; 49 (7): 1211–1215. DOI: 10.1007/s11255-017-1585-z.
21. Corsonello A., Aucella F., Pedone C., Antonelli-Incalzi R. Chronic kidney disease: a likely underestimated component of multimorbidity in older patients with chronic obstructive pulmonary disease. Geriatr. Gerontol. Int. 2017; 17 (11): 1777–1780. DOI: 10.1111/ggi.13054.
22. Mukhin N.A., Moiseev V.S., Kobalava Zh.D. Damages of the cardiovascular system in kidneys diseases. Cardiologiya: Novosti, Mneniya, Obucheniye. 2015; (2): 63–66 (in Russian).
23. Ford E.S., Murphy L.B., Khavjou O. et al. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥18 years in the United States for 2010 and projections through 2020. Chest. 2015; 147 (1): 31–45. DOI: 10.1378/chest.14-0972.
24. Bolotova E.V., Dudnikova A.V. Comparative informativeness of proteinuria tests in patients with chronic obstructive pulmonary disease. Klinicheskaya nefrologiya. 2016; (2): 33–37 (in Russian).
25. Ugay L.G., Kochetkova E.A., Nevzorova V.A. Vitamin D and respiratory diseases: molecular and clinical aspects. Dalnevostochny meditsinsky zhurnal. 2012; (3): 115–119 (in Russian).
26. Black P.N., Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey. Chest. 2005; 128 (6): 3792–3798. DOI: 10.1378/chest.128.6.3792.
27. Shen L.H., Zhang X.M., Su D.J. et al. Association of vitamin D binding protein variants with susceptibility to chronic obstructive pulmonary disease. J. Int. Med. Res. 2010; 38 (3): 1093–1098. DOI: 10.1177/147323001003800337.
28. Lee H.M., Liu M., Lee K. et al. Does low vitamin D amplify the association of COPD with total and cardiovascular disease mortality? Clin. Cardiol. 2014; 37 (8): 473–478. DOI: 10.1002/clc.22284.
29. Sanket S., Madireddi J., Stanley W. et al. Relation between vitamin D deficiency and severity of chronic obstructive pulmonary disease-a case control study. J. Clin. Diagn. Res. 2016; 10 (1): 6–19. DOI: 10.7860/jcdr/2016/15404.7097.
30. Wasse H., Cardarelli F., De Staercke C. et al. 25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. BMC Nephrol. 2011; 12 (1): 24. DOI: 10.1186/1471-2369-12-24.
31. Vestbo J., Hurd S.S., Agusti A.G. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187 (4): 347–365. DOI: 10.1164/rccm.201204-0596PP.
32. Avdeev S.N. Acute exacerbation of chronic obstructive pulmonary disease. Pul’monologiya. 2013; (3): 5–19. DOI: 10.18093/0869-0189-2013-0-3-5-19 (in Russian).
33. Heulens N., Decramer M., Janssens W. Severe vitamin D deficiency: a biomarker of exacerbation risk? Am. J. Respir. Crit. Care Med. 2013; 187 (2): 214–215. DOI: 10.1164/ajrccm.187.2.214a.
34. Puhanv M.A., Siebeling L., Frei A. et al. No association of 25-hydroxyvitamin D with exacerbations in primary care patients with COPD. Chest. 2014; 145 (1): 37–43. DOI: 10.1378/chest.13-1296.
35. Donaldson G.C., Hurst J.R., Smith C.J., Wedzicha J.A. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010; 137 (5): 1091–1097. DOI: 10.1378/chest.09-2029.
36. Halpin D.M., Decramer M., Celli B. et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT trial. Lung. 2011; 189 (4): 261–268. DOI: 10.1007/s00408-011-9301-8.
37. Kokturk N., Baha A., Oh Y.M. et al. Vitamin D deficiency: what does it mean for chronic obstructive pulmonary disease (COPD)? a compherensive review for pulmonologists. Clin. Respir. J. 2018; 12 (2): 382–397. DOI: 10.1111/crj.12588.
38. Inoue D., Watanabe R., Okazaki R. COPD and osteoporosis: links, risks, and treatment challenges. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 637–648. DOI: 10.2147/COPD.S79638.
39. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 2005; 289 (1): F8–28. DOI: 10.1152/ajprenal.00336.2004.
40. Seiler S., Heine G.H., Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int. 2009; 76 (Suppl. 114): S34–42. DOI: 10.1038/ki.2009.405.
41. Caprio M., Mammi C., Rosano G.M. Vitamin D: a novel player in endothelial function and dysfunction. Arch. Med. Sci. 2012; 8 (1): 4–5. DOI: 10.5114/aoms.2012.27271.
42. Brown J., de Boer I.H., Robinson-Cohen C. et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J. Clin. Endocrinol. Metab. 2015; 100 (2): 490–499. DOI: 10.1210/jc.2014-3949.
43. Saleh F.N., Schirmer H., Sundsfjord J., Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur. Heart J. 2003; 24 (22): 2054–2060. DOI: 10.1016/j.ehj.2003.09.010.
44. van Ballegooijen A.J., Snijder M.B., Visser M. et al. Vitamin D in relation to myocardial structure and function after eight years of follow-up: the Hoorn study. Ann. Nutr. Metab. 2012; 60 (1): 69–77. DOI: 10.1159/000336173.
45. Alvarez J.A., Law J., Coakley K. E. et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 2012; 96 (3): 672–679. DOI: 10.3945/ajcn.112.040642.
46. Turrini F., Scarlini S., Giovanardi P. et al. Effects of cholecalciferol supplementation in patients with stable heart failure and low vitamin D levels (ECSPLOIT-D): a double-blind, randomized, placebo-controlled pilot study. Minerva Cardioangiol. 2017; 65 (6): 553–562. DOI: 10.23736/S0026-4725.17.04340-7.
47. Forman J.P., Williams J.S., Fisher N.D. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension. 2010; 55 (5): 1283–1288. DOI: 10.1161/HYPERTENSIONAHA.109.148619.
48. Deb D.K., Chen Y., Zhang Z. et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am. J. Physiol. Renal Physiol. 2009; 296 (5): F1212–1218. DOI: 10.1152/ajprenal.00002.2009.
49. Boxer R.S., Hoit B.D., Schmotzer B.J. The effect of vitamin d on aldosterone and health status in patients with heart failure. J. Card. Fail. 2014; 20 (5): 334–342. DOI: 10.1016/j.cardfail.2014.01.019.
50. Wolf G., Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005; 67 (3): 799–812. DOI: 10.1111/j.1523-1755.2005.00145.x.
51. de Borst M.H., Vervloet M.G., terWee P.M., Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J. Am. Soc. Nephrol. 2011; 22 (9): 1603–1609. DOI: 10.1681/ASN.2010121251.
52. Levin A., Tang M., Perry T. et al. Randomized controlled trial for the effect of vitamin D supplementation on vascular stiffness in CKD. Clin. J. Am. Soc. Nephrol. 2017; 12 (9): 1447–1460. DOI: 10.2215/CJN.10791016.
53. Rodríguez A.J., Scott D., Srikanth V., Ebeling P. Effect of vitamin D supplementation on measures of arterial stiffness: a systematic review and meta-analysis of randomized controlled trials. Clin. Endocrinol. 2016; 84 (5): 645–657. DOI: 10.1111/cen.13031.
Review
For citations:
Bolotova E.V., Yavlyanskaya V.V., Dudnikova A.V. Cardiorenal relationships and a role of vitamin D in patients with chronic obstructive pulmonary disease. PULMONOLOGIYA. 2018;28(5):613-621. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-5-613-621
Views:
1280
Email this article 